サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1594871

アセチルコリンエステラーゼ阻害剤の世界市場、2024年～2031年

Global Acetylcholinesterase Inhibitors Market - 2024-2031

出版日
ページ情報
英文 176 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.08円
アセチルコリンエステラーゼ阻害剤の世界市場、2024年～2031年
出版日: 2024年11月21日
発行: DataM Intelligence
ページ情報: 英文 176 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

概要

アセチルコリンエステラーゼ阻害剤の世界市場は、2023年に50億3,000万米ドルとなり、2031年には90億3,000万米ドルに達し、予測期間2024年～2031年のCAGRは7.8%で成長すると予測されています。

アセチルコリンエステラーゼ阻害剤（AChEI）は、アルツハイマー病やその他の認知症を含む様々な神経疾患の治療に不可欠な特定の種類の薬剤です。これらの薬剤は、記憶、学習、筋活動に関与する重要な神経伝達物質であるアセチルコリンを分解するアセチルコリンエステラーゼという酵素を阻害することによって作用します。AChEIはアセチルコリンの分解を阻害し、アセチルコリンのレベルを上昇させ、シナプス接合部での作用を延長させることで、脳内のコリン作動性コミュニケーションを改善します。

アルツハイマー病の有病率の増加は、予測期間中の市場を牽引する要因です。例えば、国際アルツハイマー病協会（Alzheimer's Disease International）によると、世界のどこかで3秒に1人が認知症を発症しています。2020年には、世界で5,500万人以上が認知症を患うことになります。この数字は20年ごとにほぼ倍増し、2030年には7,800万人、2050年には1億3,900万人に達します。この増加の多くは低開発国で起こります。すでに認知症患者の60％が低・中所得国に住んでいるが、2050年までにその割合は71％に増加します。中国、インド、そして南アジアや西太平洋の近隣諸国が、最も急速に高齢化が進んでいます。

市場力学：

促進要因と抑制要因

神経変性疾患の有病率の増加

神経変性疾患の負担増と有病率の増加は、世界のアセチルコリンエステラーゼ阻害剤市場の成長における重要な要因になると予想されます。アルツハイマー病やその他の認知症を含む神経変性疾患の負担増と有病率の増加は、アセチルコリンエステラーゼ阻害剤世界市場の主要促進要因です。人口が高齢化し、これらの衰弱性疾患の有病率が高まるにつれて、効果的な治療法の選択肢に対する需要が高まる。

例えば、世界保健機関（WHO）によると、認知症は世界で約5,500万人が罹患しており、その60％以上が中低所得国に居住しています。毎年、およそ1,000万人が新たに発症しています。認知症は、さまざまな脳関連疾患や事故によって引き起こされます。アルツハイマー病は認知症の最も一般的なタイプであり、症例の60～70％を占めると言われています。認知症は現在、世界第7位の死因であり、高齢者の機能障害と依存の主な原因のひとつです。認知症は直接的、間接的に女性に不釣り合いな影響を与えます。認知症による障害調整生存年数や死亡率は女性の方が高いが、認知症患者の介護時間の70％も女性が占めています。

神経変性疾患の負担と有病率の増加は、アセチルコリンエステラーゼ阻害剤市場の成長を支える主な要因です。アルツハイマー病のような疾患と診断される人が増えるにつれ、効果的な治療法に対する需要が高まり、医薬品事業のこの重要なセクションにおける革新と成長につながります。研究開発への継続的な取り組みは、効果的な神経変性疾患管理のための現在の障害と将来の展望の両方に対処する上で極めて重要です。

薬剤の副作用と忍容性の問題

薬剤に伴う副作用や忍容性の問題などの要因が、世界のアセチルコリンエステラーゼ阻害剤市場を阻害すると予想されます。例えば、米国国立衛生研究所によると、アセチルコリンエステラーゼ阻害剤は利用可能なアセチルコリンの全体量を増加させる。従って、運動機能亢進、分泌過多、徐脈、ミオシス、下痢、低血圧などの副交感神経系の過剰刺激の症状が現れる可能性があります。AChEIの主な懸念事項の1つは、消化器系の副作用の発生率です。一般的な症状としては、吐き気、嘔吐、下痢、食欲不振などがあります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 神経変性疾患の罹患率の増加
      • 薬物に関連する副作用と忍容性の問題
    • 抑制要因
      • 薬物に関連する副作用と忍容性の問題
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • 償還分析
  • 特許分析
  • SWOT分析
  • DMIの見解

第6章 用途別

  • アルツハイマー病
  • パーキンソン病
  • レビー小体型認知症
  • 重症筋無力症

第7章 薬の種類別

  • ドネペジル（アリセプト）
  • ガランタミン（ラザダイン）
  • ALPHA-1062（ズンヴェイル）
  • タクリン
  • フィゾスチグミン
  • メマンチン

第8章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • その他

第9章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 中東・アフリカ

第10章 競合情勢

  • 競合シナリオ
  • 市況・シェア分析
  • M&A分析

第11章 企業プロファイル

  • Eisai Co., Ltd.
    • 会社概要
    • 製品ポートフォリオと概要
    • 財務概要
    • 主な発展
  • Pfizer Inc.
  • Alkem
  • Zydus Group
  • Teva Pharmaceutical Industries Ltd
  • Indena S.p.A.
  • Alpha Cognition
  • Dr. Reddy's Laboratories Ltd.
  • Aurobindo Pharma
  • Merz Pharma

第12章 付録

目次
Product Code: PH8778

Overview

The global acetylcholinesterase inhibitors market reached US$ 5.03 billion in 2023 and is expected to reach US$ 9.03 billion by 2031, growing at a CAGR of 7.8% during the forecast period 2024-2031.

Acetylcholinesterase inhibitors (AChEIs) are a specific kind of drug that is essential in the treatment of a variety of neurological illnesses, including Alzheimer's disease and other forms of dementia. These medications work by blocking the enzyme acetylcholinesterase, which breaks down acetylcholine, a critical neurotransmitter involved in memory, learning, and muscular activity. AChEIs block acetylcholine breakdown, increasing its levels and prolonging its effect at synaptic junctions, hence improving cholinergic communication in the brain.

The increasing prevalence of alzheimer's disease is the driving factor that drives the market over the forecast period. For instance, according to Alzheimer's Disease International, Every three seconds, someone somewhere in the globe develops dementia. In 2020, more than 55 million individuals globally will be living with dementia. This figure will nearly double every twenty years, reaching 78 million in 2030 and 139 million in 2050. Much of the increase will occur in underdeveloped countries. Already, 60% of people with dementia live in low- and middle-income nations, by 2050, the proportion will grow to 71%. China, India, and their South Asian and Western Pacific neighbors are experiencing the fastest aging population rise.

Market Dynamics: Drivers & Restraints

Increasing prevalence of neurodegenerative diseases

The rising burden and increasing prevalence of neurodegenerative diseases is expected to be a significant factor in the growth of the global acetylcholinesterase inhibitors market. The increased burden and prevalence of neurodegenerative disorders, including Alzheimer's disease and other types of dementia, are key drivers of the global acetylcholinesterase inhibitors market. As the population ages and the prevalence of these debilitating disorders increases, there will be a greater demand for effective therapeutic choices.

For instance, according to the World Health Organization, Dementia affects around 55 million individuals globally, with more than 60% living in low- and middle-income countries. Every year, there are roughly 10 million new cases. Dementia is caused by a range of brain-related disorders and accidents. Alzheimer's disease is the most common type of dementia and may account for 60-70% of cases. Dementia is now the seventh largest cause of death and one of the primary causes of impairment and dependency among the elderly worldwide. Women are disproportionately impacted by dementia, both directly and indirectly. Women had greater disability-adjusted life years and mortality rates from dementia, but they also gave 70% of care hours for people with dementia.

The increased burden and prevalence of neurodegenerative disorders are major factors supporting the growth of the acetylcholinesterase inhibitors market. As more people are diagnosed with diseases such as Alzheimer's disease, the demand for effective treatments will increase, leading to innovation and growth in this vital section of the pharmaceutical business. The continuous commitment to research and development will be critical in addressing both present obstacles and future prospects for effective neurodegenerative disease management.

Side Effects and Tolerability Issues Associated with Drugs

Factors such as side effects and tolerability issues associated with drugs are expected to hamper the global acetylcholinesterase inhibitors market. For instance, according to the National Institute of Health, acetylcholinesterase inhibitors increase the overall amount of acetylcholine available. Thus, symptoms of overstimulation of the parasympathetic nervous system, such as increased hypermotility, hypersecretion, bradycardia, miosis, diarrhea, and hypotension, may be present. One of the primary concerns with AChEIs is the incidence of gastrointestinal adverse effects. Common symptoms include nausea, vomiting, diarrhea, and anorexia.

Segment Analysis

The global acetylcholinesterase inhibitors market is segmented based on application, drug type, distribution channel, and region.

Alzheimer's disease segment is expected to dominate the global acetylcholinesterase inhibitors market share

Alzheimer's disease segment is expected to dominate the global acetylcholinesterase inhibitors market share. The Alzheimer's disease market is anticipated to dominate the global acetylcholinesterase inhibitors market, owing to the disease's increasing prevalence and the growing acceptance of acetylcholinesterase inhibitors (AChEIs) as a conventional treatment. Alzheimer's disease, the most common type of dementia, affects millions of people globally, and its rising prevalence is a major factor driving the growth of this market sector. For instance, according to the Alzheimer's Association, Alzheimer's dementia affects around 6.7 million Americans aged 65 and older. If no medical breakthroughs are developed to prevent, halt, or cure Alzheimer's disease, this figure might rise to 13.8 million by 2060. In 2019, official death certificates documented 121,499 deaths from Alzheimer's disease, making it the sixth-highest cause of death in the United States.

The acetylcholinesterase inhibitors play an important role in the treatment of alzheimer's disease. Acetylcholinesterase inhibitors, including donepezil, rivastigmine, and galantamine, are among the few approved pharmaceutical treatments for Alzheimer's disease symptoms. These drugs act by preventing the breakdown of acetylcholine, a neurotransmitter necessary for memory and cognitive function. AChEIs, which increase acetylcholine levels in the brain, can assist improve cognitive performance and halt symptom development in people with mild to moderate Alzheimer's disease. Numerous clinical trials have supported the efficacy of these medications, confirming their status as an essential component in Alzheimer's treatment.

Geographical Analysis

North America is expected to hold a significant position in the global acetylcholinesterase inhibitors market share

North America is expected to hold a significant portion of the global acetylcholinesterase inhibitors market. North America is expected to dominate the global acetylcholinesterase inhibitors market, owing to demographic trends, high prevalence rates of neurological disorders, and developments in healthcare infrastructure. As the region experiences an increase in the number of people diagnosed with Alzheimer's disease and other forms of dementia, there will be a greater demand for effective treatment alternatives like acetylcholinesterase inhibitors.

For instance, according to the Alzheimer's Association, Alzheimer's affects around 7 million Americans. By 2050, this figure is expected to increase to approximately 13 million. Alzheimer's disease was the fifth greatest cause of mortality for those aged 65 and up. Health and long-term care costs for people with dementia are expected to exceed $360 billion in 2024 and nearly $1 trillion by 2050. At the age of 45, women have a one-in-five lifetime risk of developing Alzheimer's, while males have one in ten. Over 11 million Americans offer unpaid care to persons suffering from Alzheimer's disease or other forms of dementia.

North America has an established healthcare system, making improved therapeutic choices available to patients suffering from neurodegenerative illnesses. The region is home to various research institutions and pharmaceutical businesses that develop and market AChEIs, ensuring that patients have access to the most recent therapy options. The availability of well-established hospital systems, outpatient facilities, and specialized dementia care centers improves patient access to critical drugs and supportive services.

Asia Pacific is growing at the fastest pace in the global acetylcholinesterase inhibitors market

The Asia Pacific area is emerging as the fastest-growing market for acetylcholinesterase inhibitors (AChEIs), owing to a combination of demographic, healthcare, and economic drivers. As the frequency of neurodegenerative disorders, particularly Alzheimer's disease and other kinds of dementia, rises in this highly populated region, there will be a huge increase in demand for effective therapy choices. For instance, according to the Alzheimer's Association, The estimated dementia prevalence in individuals aged 60 and up in India is 7.4%. There are an estimated 8.8 million Indians over the age of 60 who suffer from dementia. Dementia affects more women than men, and it is more prevalent in rural regions than in cities.

Competitive Landscape

The major global players in the global acetylcholinesterase inhibitors market include Eisai Co., Ltd., Pfizer Inc., Alkem, Zydus Group, Teva Pharmaceutical Industries Ltd, Indena S.p.A., Alpha Cognition, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma, Merz Pharma among others.

Emerging Players

Biogen, Anavex Life Sciences Corp. among others

Key Developments

  • In July 2024, the U.S. FDA approved Alpha Cognition Inc.'s ALPHA-1062 (Zunveyl(R)), an Acetylcholinesterase (AChE) inhibitor, for treating mild-to-moderate Alzheimer's disease. ALPHA-1062 is absorbed in the small intestine as an insert medication. The addition of a benzyl ester to galantamine inhibits its binding to AChE in the gastrointestinal nervous system. This minimizes overstimulation of local neurons, and gastrointestinal adverse events, and enhances absorption.

Why Purchase the Report?

  • To visualize the global acetylcholinesterase inhibitors market segmentation based on application, drug type, distribution channel, and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of global acetylcholinesterase inhibitors market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global acetylcholinesterase inhibitors market report would provide approximately 53 tables, 47 figures, and 176 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Application
  • 3.2. Snippet by Drug Type
  • 3.3. Snippet by Distribution Channel
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Prevalence of Neurodegenerative Diseases
      • 4.1.1.2. Side Effects and Tolerability Issues Associated with Drugs
    • 4.1.2. Restraints
      • 4.1.2.1. Side Effects and Tolerability Issues Associated with Drugs
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Patent Analysis
  • 5.7. SWOT Analysis
  • 5.8. DMI Opinion

6. By Application

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 6.1.2. Market Attractiveness Index, By Application
  • 6.2. Alzheimer's Disease*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Parkinson Disease
  • 6.4. Lewy Body Dementia
  • 6.5. Myasthenia Gravis

7. By Drug Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 7.1.2. Market Attractiveness Index, By Drug Type
  • 7.2. Donepezil (Aricept)*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Galantamine (Razadyne)
  • 7.4. ALPHA-1062 (Zunveyl)
  • 7.5. Tacrine
  • 7.6. Physostigmine
  • 7.7. Memantine

8. By Distribution Channel

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 8.1.2. Market Attractiveness Index, By Distribution Channel
  • 8.2. Hospital Pharmacy*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Retail Pharmacy
  • 8.4. Online Pharmacy
  • 8.5. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. The U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. UK
      • 9.3.6.3. France
      • 9.3.6.4. Italy
      • 9.3.6.5. Spain
      • 9.3.6.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. South Korea
      • 9.5.6.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Eisai Co., Ltd.*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. Pfizer Inc.
  • 11.3. Alkem
  • 11.4. Zydus Group
  • 11.5. Teva Pharmaceutical Industries Ltd
  • 11.6. Indena S.p.A.
  • 11.7. Alpha Cognition
  • 11.8. Dr. Reddy's Laboratories Ltd.
  • 11.9. Aurobindo Pharma
  • 11.10. Merz Pharma

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us